AAPGV: Multiplikator P/S Ascentage Pharma Group Ltd
The biotech sector possesses macro-resilience, as medical progress remains independent of GDP. High R&D costs and patents create an insurmountable barrier for competitors. Changes in the price-to-sales ratio confirm these theses, and 8.50 captures the current state of the parameter. Ascentage Pharma Group (AAPGV) focuses on targeted leukemia therapy in the US and China, developing drugs to combat chemotherapy resistance.
Rincian metrik lan analitis perusahaan Ascentage Pharma Group Ltd (AAPGV)
- kuotasi saiki lan rata-rata prakiraan nilai:
- informasi kapitalisasi pasar:
- data ekuitas miturut neraca:
- indikator beban kredit lan likuiditas emiten:
Utang marang Modal Ascentage Pharma Group|AAPGV - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Ascentage|AAPGV - Gunggung utang perusahaan|Utang marang modal buku Ascentage Pharma Group Ltd|AAPGV - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Ascentage Pharma|Likuiditas kritis ascentage.com
- data bathi resik lan rasio valuasi:
AAPGV - Bathi resik|Bathi resik sing dikarepake Ascentage Pharma Group|AAPGV - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi Ascentage Pharma Group International|AAPGV - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi operasional sadurunge panyusutan Ascentage Pharma Group Ltd|AAPGV - Bathi operasional EBITDA|Bathi saben saham sajroning taun lumaku Ascentage Pharma|AAPGV - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan ascentage.com|AAPGV - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Ascentage Pharma Group
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:ascentage.com
For Ascentage Pharma Group (AAPGV), whose potential in oncohematology is confirmed by international recognition, the P/S market multiple serves as an indicator for valuing future cash flows relative to current sales. This ratio is calculated as the relationship between market capitalization and annual revenue, allowing investors to determine whether the business is overvalued or to identify undervalued assets within the context of the company's therapeutic prospects.
Perusahaan pesaing
ONC - Rega marang dodolan|Multiplikator P/S HALO (Halozyme)|Multiplikator P/S Revolution Medicines Inc RVMD|AAPG - Rasio rega marang pendapatan|Koefisien rega marang pendapatan CG Oncology Therapeutics CGON|URGN: Multiplikator P/S|Kapitalisasi marang pendapatan bicara.com|PSNL (Personalis) - Multiplikator P/S|Rega marang dodolan Erasca Inc ERAS|Rasio rega marang pendapatan Delcath (DCTH)|Y-mAbs Corp - Rasio kapitalisasi marang pendapatan|Aura Biosciences, Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan CADL (Candel Therapeutics Inc.)|Accuray - Multiplikator P/S|SLS - Multiplikator P/S|ACTU: Multiplikator P/S|Multiplikator rega marang pendapatan Citius Oncology Inc CTOR|HURA (TuHURA Biosciences Inc.) - Multiplikator P/S|Rega marang dodolan protaratx.com TARA|Kapitalisasi marang pendapatan FATE (Fate Therapeutics)|WHWK (aadibio.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan TScan Therapeutics, Inc. TCRX|CSBR (Champions Oncology Inc) - Rasio rega marang dodolan|XBiotech USA - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan CVM (CEL-SCI Corporation)|OSTX: Multiplikator P/S|radiopharmtheranostics.com (RADX) - Multiplikator P/S|Rasio rega marang pendapatan Artiva Biotherapeutics Inc.|ANL: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Veru Inc. (VERU)|Kapitalisasi marang pendapatan tempesttx.com TPST|Multiplikator P/S XLO (Xilio Therapeutics)|Multiplikator P/S Renovaro Biosciences RENB|MURA: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan KAPA (Kairos Pharma Ltd)|OKUR: Multiplikator P/S|Multiplikator rega marang pendapatan CytoMed Therapeutics Limited GDTC|Rasio rega marang pendapatan Curis Inc.|APLM: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Tharimmune Corp (THAR)|ADVB - Rega marang dodolan|Genprex, Inc. - Kapitalisasi marang pendapatan|Multiplikator P/S Calidi Biotherapeutics Inc. CLDI|SBFM - Rasio rega marang pendapatan|Rasio rega marang dodolan XBIO|SLRX: Multiplikator P/S|Kitov Pharma (PPBT) - Multiplikator P/S|AONC (American Oncology Network Inc) - Multiplikator P/S|Multiplikator P/S beigene.com|Rasio rega marang pendapatan Checkpoint Therapeutics, Inc. (CKPT)|ELEV: Rasio rega marang dodolan|Multiplikator P/S ICAD (iCAD)|Multiplikator rega marang pendapatan Ikena Oncology Inc.|NTBL: Kapitalisasi marang pendapatan|VIRX: Rasio rega marang pendapatan|MOR: Multiplikator P/S|Kapitalisasi marang pendapatan NAYA Biosciences Inc
